Main Article Content
method. The optimized formulation consisted of glycerol mono-oleate (10%, w/w), tween 80 (36%, w/w), polyethylene glycol 400 (27%, w/w), and propylene glycol (27%, w/w) with a drug content of about 8 mg per ml. The self-emulsifying formulation showed 100% dissolution within 30 minutes whereas the pure drug exhibited a very poor rate of dissolution.In vitro intestinal permeability was studied by noneverted intestinal sac method using rat intestine. The self-emulsifying formulation showed 100% drug permeation within 30 minutes compared to negligible permeation from the drug suspension.
The study demonstrates that SEDDS approach may be useful for enhancement of dissolution and intestinal permeation of amphotericin B belonging to class IV of Biopharmaceutic Classification System.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Pouton CW. Lipid formulations for oral administration of drugs: Non-
emulsifying, self-emulsifying and â€˜self-microemulsifyingâ€™ drug delivery
systems. Eur J Pharm Sci 2000;11:S93-8.
Constantinides PP. Lipid microemulsions for improving drug dissolution
and oral absorption: Physical and biopharmaceutical aspects. Pharm
Kim HJ, Yoon KA, Hahn M, Park ES, Chi SC. Preparation and in vitro
evaluation of self-microemulsifying drug delivery systems containing
idebenone. Drug Dev Ind Pharm 2000;26:523-9.
Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004;274:65-73.
Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying
drug delivery systems (SEDDS) with polyglycolysed glycerides for
improving in vitro dissolution and oral absorption of lipophilic drugs.
Int J Pharm 1994;106:15-23.
Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ,
Pouton CW. Self-emulsifying drug delivery systems: Formulation and
biopharmaceutic evaluation of an investigational lipophilic compound.
Pharm Res 1992;9:87-93.
Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug
delivery systems (SEDDS) of coenzyme Q10: Formulation development
and bioavailability assessment. Int J Pharm 2001;212:233-46.
Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS)
for improved oral delivery of lipophilic drugs. Biomed Pharmacother
Meyer RD. Current role of therapy with amphotericin B. Clin Infect Dis
Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P.
Comparison of three treatment regimens with liposomal amphotericin
b (Ambisome) for visceral leishmaniasis in India: A randomized dose
finding study. Trans R Soc Trop Med Hyg 1996;90:319-22.
Rajagopalan N, Chen SC, Chow W. A study of the inclusion complex of
amphotericin B with î§-cyclodextrin. Int J Pharm 1986;29:161-8.
Bajpai M, Verma KC. Studies on amphotericin B solid dispersions
prepared using blend of carriers. The Eastern Pharmacist 1981;24:187-8.
Dangi JS, Vyas SP, Dixit VK. Effect of various lipid-bile salt mixed micelles on the intestinal absorption of amphotericin B in rat. Drug Dev Ind
Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of
amphotericin B as nanosuspension for oral administration. Int J Pharm
Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L, et al.
Efficacy of oral cochleate-amphptericin B in a mouse model of systemic
candidiasis. Antimicrob Agent Chemother 2000;44:2356-60.
Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ. Antifungal activity of Amphotericin B cochleates against candida albicans infectionin a mouse model. Antimicrob Agent Chemother 2000;44:1463-9.
Risovic V, Sachs-Barrable K, Boyd M, Wasan KM. Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin
B. Drug Dev Ind Pharm 2004;30:767-74.
Wasan EK, Bartlett K, Gershkovich P, Sivak O, Banno B, Wong Z, et al.
Development and characterization of oral lipid-based amphotericin B
formulations with enhanced drug solubility, stability and antifungal
activity in rats infected with Aspergillus fumigatus or Candida albicans.
Int J Pharm 2009;372:76-84.
Gershkovich P, Wasan EK, Lin M, Sivak O, Leon CG, Clement JG, et al.
Pharmacokinetics and biodistribution of amphotericin B in rats
following oral administration in a novel lipid-based formulation.
J Antimicrob Chemother 2009;64:101-8.
Risovic V, Boyd M, Choo E, Wasan KM. Effects of lipid-based oral
formulations on plasma and tissue amphotericin B concentrations
and renal toxicity in male rats. Antimicrob Agent Chemother
WÃ¼rthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM,
Walsh TJ, et al. Population pharmacokinetics of amphotericin B
lipid complex in neonates. Antimicrob Agent Chemother 2005;
Ruan LP, Chen S, Yu BY, Zhu DN, Cordell GA, Qiu SX. Prediction of human
absorption of natural compounds by the non-everted rat intestinal sac
model. Eur J Med Chem 2006;41:605-10.
Yamsani SK, Gannu R, Devandla A, Yamsani VV, Palem CR, Ravula SK,
et al. Effect of silymarin and pomegranate pretreatment on intestinal
transport of buspirone across rat intestine. Acta Pharmaceutica Sciencia
Adams ML, Kwon GS. Relative aggregation state and hemolytic activity
of amphotericin B encapsulated by poly(ethylene oxide)-block-poly
(N-hexyI-I-aspartamide)acyl conjugate micelles: Effects of acyl chain
length. Biochim Biophys Acta 1980;599:280-93.
Johnson BM, Charman WN, Porter CJ. An in vitro examination of the
impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-
tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein
efflux and enterocyte-based metabolism in excised rat intestine. AAPS
Zhang H, Yao M, Morrison RA, Chong S. Commonly used surfactant,
Tween 80, improves absorption of P-glycoprotein substrate, digoxin,
in rats. Arch Pharm Res 2003;26:768-72.